Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENLON-PLUS vs ADDERALL 30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enlon-Plus (neostigmine methylsulfate and glycopyrrolate) is a combination of a reversible acetylcholinesterase inhibitor (neostigmine) and an anticholinergic agent (glycopyrrolate). Neostigmine inhibits acetylcholinesterase, increasing acetylcholine concentration at cholinergic synapses, enhancing neuromuscular transmission. Glycopyrrolate counteracts muscarinic side effects (e.g., bradycardia, excessive secretions) without affecting nicotinic actions.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Reversal of non-depolarizing neuromuscular blocking agents after surgery,Off-label: Treatment of myasthenia gravis (neostigmine component)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
1 to 2 m L (0.5 to 1 mg neostigmine methylsulfate with 0.2 to 0.4 mg glycopyrrolate) IV over 1 minute; may repeat in 10-15 minutes if needed; maximum total dose: 5 m L.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
Terminal elimination half-life: 3.5–4.5 hours (prolonged in hepatic impairment).
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Neostigmine: Hydrolyzed by cholinesterases and metabolized in the liver via microsomal enzymes. Glycopyrrolate: Not significantly metabolized; eliminated unchanged in urine and bile.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Plasma protein binding: 55–65%, primarily to albumin.
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Vd: 0.8–1.2 L/kg, indicating distribution into total body water.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Oral: 70–80% (first-pass effect); IM: 100%.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
Cr Cl 10-50 m L/min: Use 50% of dose. Cr Cl <10 m L/min: Use 25% of dose. Adjust based on neostigmine component due to renal excretion.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
No specific adjustment required; neostigmine minimally hepatically metabolized.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
0.04 mg/kg neostigmine methylsulfate with 0.02 mg/kg glycopyrrolate IV; may repeat in 10-15 minutes if needed; maximum single dose: 2 m L.
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Use with caution; consider lower initial doses due to potential renal impairment; monitor for bradycardia and excessive cholinergic effects.
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
Should be used only when facilities for immediate endotracheal intubation, artificial respiration, and oxygen therapy are available. Bradycardia and cardiac arrest have occurred. Administer in the presence of an anesthesiologist or other qualified clinician.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Risk of severe bradycardia, hypotension, and cardiac arrest. Use caution in patients with asthma, epilepsy, bradyarrhythmias, recent myocardial infarction, or hyperthyroidism. May increase bronchial secretions. Avoid in patients with mechanical obstruction of the gastrointestinal or urinary tract.
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Known hypersensitivity to neostigmine, glycopyrrolate, or any component. Contraindicated in patients with peritonitis, mechanical intestinal obstruction, or urinary tract obstruction.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
No specific food interactions are reported. Maintain adequate hydration. Avoid excessive caffeine or alcohol, which may affect heart rate or fluid balance.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
First trimester: No adequate studies in pregnant women; animal studies not available. Risk cannot be ruled out. Second/third trimester: Potential fetal toxicity (respiratory depression, bradycardia) if used near term. Avoid use during labor due to risk of neonatal respiratory depression.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
Not recommended. Unknown M/P ratio. Atropine and pralidoxime (components of ENLON-PLUS) may enter breast milk; potential for infant anticholinergic effects and gastrointestinal disturbances.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
No established dose adjustments. Increased plasma volume and renal clearance in pregnancy may reduce drug concentrations; however, no pharmacokinetic studies available. Titrate to effect with caution.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
ENLON-PLUS (neostigmine/glycopyrrolate) is used for reversal of non-depolarizing neuromuscular blockade. Neostigmine inhibits acetylcholinesterase, increasing ACh at the neuromuscular junction; glycopyrrolate is an anticholinergic to counteract muscarinic side effects (bradycardia, excessive secretions). Monitor heart rate closely; glycopyrrolate may cause tachycardia. Administer IV slowly over 1 minute. Onset is 5-10 minutes; peak effect at 10-20 minutes. Use with caution in patients with bradycardia, asthma, or peptic ulcer disease.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
This medication is given to reverse muscle relaxants after surgery.,You may experience changes in heart rate; tell your doctor if you feel palpitations or chest discomfort.,Dry mouth and blurred vision are possible side effects due to the glycopyrrolate component.,Inform your healthcare provider if you have a history of heart problems, asthma, or stomach ulcers.,You may feel temporary muscle weakness or twitching as the medication works.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENLON-PLUS vs ADDERALL 30, answered by our medical review team.
ENLON-PLUS is a Cholinesterase Inhibitor Combination that works by Enlon-Plus (neostigmine methylsulfate and glycopyrrolate) is a combination of a reversible acetylcholinesterase inhibitor (neostigmine) and an anticholinergic agent (glycopyrrolate). Neostigmine inhibits acetylcholinesterase, increasing acetylcholine concentration at cholinergic synapses, enhancing neuromuscular transmission. Glycopyrrolate counteracts muscarinic side effects (e.g., bradycardia, excessive secretions) without affecting nicotinic actions.. ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENLON-PLUS and ADDERALL 30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENLON-PLUS is: 1 to 2 m L (0.5 to 1 mg neostigmine methylsulfate with 0.2 to 0.4 mg glycopyrrolate) IV over 1 minute; may repeat in 10-15 minutes if needed; maximum total dose: 5 m L.. The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENLON-PLUS and ADDERALL 30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENLON-PLUS is classified as Category C. First trimester: No adequate studies in pregnant women; animal studies not available. Risk cannot be ruled out. Second/third trimester: Potential fetal toxicity (respiratory depres. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.